Dr. Burris on Using Recurrence Scores to Predict pCR

Video

Dr. Howard Burris from Sarah Cannon Research Institute Discusses Recurrence Scores Predicting pCR

Howard A. "Skip" Burris, III, MD, chief medical officer and executive director, Drug Development Program, Sarah Cannon Research Institute in Nashville, Tennessee, discusses the correlation between pathological complete response (pCR) and Oncotype DX recurrence scores (RS).

A phase II study that examined ixabepilone and cyclophosphamide as neoadjuvant therapy in HER2-negative breast cancer patients found that patients with a high RS (greater than 31) or rapidly proliferating tumors responded better to chemotherapy, with 26% demonstrating a pCR. None of the patients in the trial with a low to intermediate RS experienced pCR.

The trial demonstrated that rapidly proliferating tumors are more susceptible to chemotherapy. Biologics may make a difference and still needs to be explored further in future clinical trials.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute